Techbase Medical Defense (ATD)
Abstract
Project TM3 supports preclinical and early phase clinical development of vaccines, therapeutic drugs, and diagnostic capabilities to provide safe and effective medical defense against validated biological threat agents or emerging infectious disease biothreats including bacteria, toxins, and viruses. In FY2023, the CBDP RDT&E Projects have been restructured to align to the CBDP portfolio. TM3 thrust areas in FY2022 progress to the Enabling Investments (EN3), Mitigate (MT3), Protect (PT3), and Understand (UN3) portfolios. This restructuring is intended to provide standardization and alignment across CBDP research, development and acquisition efforts. Individual efforts in this project include: -Innovative biotechnology approaches to advance medical systems designed to rapidly identify, diagnose, prevent, and treat disease due to exposure to biological threat agents will be evaluated. -Rapid development of medical countermeasure solutions is a crucial modernization strategy to avoid technological surprise against an expanding and sophisticated biological WMD threat. Techbase Medical Defense (ACD&P), therefore, supports the Discovery of Medical Countermeasures Against New and Emerging (DOMANE) threat thrust, which is designed to develop technologies that support understanding, mitigating, and protecting against new and emerging biological threats to include viral, bacterial, and biotoxins. -Supports the advanced development of medical countermeasures to include prophylaxes, pretreatments, antidotes and therapeutic drugs against new and emerging biological threats. Demonstration of safety and toxicity data through adaptive trials for repurposed FDA-approved drugs, novel broad-spectrum drugs and drug combinations supporting submitting Investigational New Drug (IND) processes or Emergency Use Authorizations (EUA). Additionally, this effort supports development of technologies that protect, mitigate and understand new and emerging threats by forecasting pathogenesis and toxicity, structural determinations utilizing high throughput systems to identify both host and pathogen targets using advanced AI and a curated repository of high-resolution 3D macromolecular structures to generate drug candidates.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2023
- Source ID
- TM3_0603384BP_3_0400_PB_2023
Related Documents
- Root: CHEMICAL/BIOLOGICAL DEFENSE (ATD)
- Child Accomplishment: 1) Internal COVID - VSV SARS CoV-2 vaccine
- Child Accomplishment: 2) Battlefield Readiness
- Child Accomplishment: 3) Battlefield Readiness
- Child Accomplishment: 4) Chemical Diagnostics
- Child Accomplishment: 5) Chemical Diagnostics
- Child Accomplishment: 6) Clinical Evaluation
- Child Accomplishment: 7) Emerging Threats
- Child Accomplishment: 8) Emerging Threats
- Child Accomplishment: 9) Diagnostic Building Blocks
- Child Accomplishment: 10) Diagnostic Building Blocks
- Child Accomplishment: 11) Nerve Agent Prophylaxis/Pretreatments
- Child Accomplishment: 12) Pharmaceutical Based Agents (PBAs)
- Child Accomplishment: 13) Reactivators of AChE as Therapeutics (ReACT)
- Child Accomplishment: 14) Bacterial Therapeutics
- Child Accomplishment: 15) Viral Therapeutics
- Child Accomplishment: 16) Toxin Therapeutics
- Child Accomplishment: 17) Medical Countermeasures Initiative
- Child Accomplishment: 18) Bacterial/Viral/Toxin/Broad Spectrum Prophylaxis